Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma

Anti-Cancer Drugs

Volumn 10, Issue 9, 1999, Pages 815-819

  Corona, Giuseppe ^b   Aita, Paola ^b   Sorio, Roberto ^a,b   Colussi, Anna Maria ^a,b   Bearz, Alessandra ^a,b   Sartor, Franca ^b   Boiocchi, Mauro ^a,b   Toffoli, Giuseppe ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Division of Experimental Oncology 1   (Italy)

Author keywords

Etoposide; Hepatocellular carcinoma; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; TAMOXIFEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL;

EID: 0033455607     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199910000-00004     Document Type: Article

References (20)

1. 1. Chlebowski RT, Butler J, Nelson A, Lillington L. Breast cancer chemoprevention. Tamoxifen: current issues and future prospective. Cancer 1993; 72: 1032-7.
2. 2. Higginson J, Gelmann EP. Scientific review of tamoxifen. Semin Oncol 1997; 24 (suppl 1): 1-4.
3. 3. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 1997; 24 (suppl 1): 65-70.
4. 4. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997; 15: 1385-94.
5. 5. Wiseman H. Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol Sci 1994; 15: 83-9.
6. 6. Berman E, Adams M, Duigou Osterndorf R, Godfrey L, Clarkson B, Andreeff M. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 1991; 77: 818-25.
7. 7. Trump DL, Smith OC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992; 84: 1811-6.
8. 8. Millward MJ, Lien EA, Robinson A, Cantwell BM. High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator. Oncology 1994; 51: 79-83.
9. 9. Cheng AL, Chen YC, Yeh KH, Chuang SE, Chen BR, Chen DS. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 1996; 77: 872-7.
10. 10. Lum BL, Fisher GA, Brophy NA, et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 1993; 72: 3502-14.
11. 11. Toffoli G, Sorio R, Gigante M, Corona G, Galligioni E, Boiocchi M. Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide. Br J Cancer 1997; 75: 715-21.
12. 12. Aita P, Robieux I, Sorio R, et al. Pharmacokinetics of oral etoposide in patients with hepatocelular carcinoma. Cancer Chemother Pharmacol 1999; 43: 287-94.
13. 13. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future Cancer Treat Rev 1988; 15: 1-31.
14. 14. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-42.
15. 15. Bisogno G, Cowie F, Boddy A, Thomas HD, Dick G, Pinkerton CR. High dose cyclosporin with etoposide -toxicity and pharmacokinetic interaction in children with solid tumours. Br J Cancer 1998; 77: 2304-9.
16. 16. Stewart CF, Arbuck SG, Fleming RA, Evans WE. Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 1991; 50: 385-93.
17. 17. Joel S. The clinical pharmacology of etoposide: an update. Cancer Treat Rev 1996; 22: 179-221.
18. 18. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991; 51: 4837-44.
19. 19. Bignon E, Pons M, Dore JC, et al. Influence of di-and triphenylethylene estrogen/antiestrogen structure on the mechanisms of protein kinase C inhibition and activation as revealed by a multivariate analysis. Biochem Pharmacol 1991; 42: 1373-83.
20. 20. Butta A, MacLennan K, Flanders KC, et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261-4.